Skip to main content
    U

    Uniqure NV (QURE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $21.88
    -1.93 (-8.11%)

    Market Cap: $1.67B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Uniqure NV (QURE) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Uniqure NV (QURE) trades at 75.8x sales and 5.2x book value. Its P/S of 75.8x is above its 5-year median of 14.2x. Its forward P/E is 27.9x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E27.9x
    Price to sales75.8x
    Price to book5.2x
    PEGN/A
    FCF yield-12.6%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 113.5% above 35.5x and its P/B is 10.3% below 5.8x.

    MultipleCurrent5-year median10-year median
    P/S75.8x14.2x35.5x
    P/B5.2x2.2x5.8x
    Medians of month-end values through Oct 2026: 54 to 60 months (5-year) and 114 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 1.8x in 2021 to 383.5x in 2019.

    Year endPriceP/EP/SP/B
    2025$23.93N/A83.8x6.9x
    2024$17.66N/A31.6xN/A
    2023$6.77N/A20.4x1.6x
    2022$22.67N/A10.0x2.2x
    2021$20.743.5x1.8x1.6x
    2020$36.13N/A42.8x6.6x
    2019$71.66N/A383.5x8.9x
    2018$28.82N/A89.1x5.7x
    2017$19.59N/A38.6x5.9x
    2016$5.60N/A5.6x2.2x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    Frequently Asked Questions About QURE

    What is QURE's forward P/E ratio?

    Uniqure NV has a forward P/E ratio of 27.9x.

    What is QURE's price to sales ratio?

    Uniqure NV has a price to sales ratio of 75.8x.